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Phthalates are high­production­volume 
chemicals. Some phthalates are used as sol­
vents and additives and are often found in 
personal care products, such as cosmetics, 
lotions, and perfumes, and in the coatings of 
some medications (David et al. 2001; Koch 
and Calafat 2009; Schettler 2006). Others, 
including diisononyl phthalate (DINP) and 
diisodecyl phthalate (DIDP), are used pri­
marily as plasticizers of polyvinyl chloride 
(PVC) and may be used in PVC flooring, 
wall coverings, building materials, heat­re­
sistant electrical cords, car interiors, and toys 
(David et al. 2001; Koch and Calafat 2009; 
Schettler 2006).
Historically, toxicologic studies of phtha­
lates have focused on liver effects in rodents 
and the toxicologic relevance of these effects 
to humans (European Commission 2003a, 
2003b). Recently, attention has been given 
to the potential for some phthalates, includ­
ing DINP, to affect reproductive outcomes 
and the development of the male reproductive 
tract (Adamsson et al. 2009; Borch et al. 2006; 
Gray and Gangolli 1986; Gray et al. 2000; 
Howdeshell et al. 2007; Kavlock et al. 2002b; 
Masutomi et al. 2003; Waterman et al. 2000); 
these phthalates can alter sexual differentia­
tion of the male rat by inhibiting fetal testicu­
lar testosterone synthesis (Foster 2006; Gray 
et al. 2000; Lee et al. 2004; Sharpe and Irvine 
2004; Tyl et al. 2004). Other phthalates, such 
as DIDP, can also produce rodent liver effects 
(European Commission 2003a) but have not 
been shown to affect reproductive outcomes 
(Hushka et al. 2001; Kavlock et al. 2002a). 
Compared with the large body of experimental 
evidence suggesting reproductive or develop­
mental toxicity of phthalates, human data 
are rather limited (Hauser and Calafat 2005; 
Meeker et al. 2009). Nevertheless, in light of 
concerns about the potential adverse health 
effects of phthalates in humans, the European 
Union has banned several phthalates from cos­
metics [National Research Council (NRC) 
2008], and several countries, including the 
United States, have legislation restricting the 
use of certain phthalates in some children’s 
products, such as toys. The Consumer Product 
Safety Commission (CPSC) is currently evalu­
ating whether to lift or make permanent the 
temporary restrictions, which became effective 
in February 2009, on the sale of children’s toys 
that can be placed in a child’s mouth and on 
child care articles that contain > 0.1% DINP, 
DIDP or di­n­octyl phthalate (CPSC 2009).
After exposure, phthalates are rapidly 
metabolized to their corresponding hydrolytic 
monoesters, which can be further transformed 
to hydrophilic oxidative products, conjugated, 
and eliminated (Koch and Calafat 2009). For 
the past 2 decades, urinary concentrations of 
these phthalate metabolites have been meas­
ured as part of biomonitoring programs or 
epidemiologic studies, mainly in the United 
States and Germany [Angerer et al. 2006; 
Becker et al. 2009; Centers for Disease Control 
and Prevention (CDC) 2009] and, to a lesser 
extent, in other countries, to assess exposure of 
the general population to phthalates.
Biomonitoring data have consistently 
shown widespread human exposure to mul­
tiple phthalates (Becker et al. 2009; CDC 
2009; Koch and Calafat 2009; NRC 2008). 
By contrast, for other phthalates, particu­
larly high­molecular­weight phthalates such 
as DINP, the exposure appears to be rather 
limited, based on the concentrations of the 
corresponding hydrolytic monoesters [e.g., 
monoisononyl phthalate (MNP)] (CDC 
2009; Silva et al. 2004). However, other 
research suggests that the low frequency of 
detection of MNP, a metabolite of DINP, 
in human populations may be attributable 
partly to the fact that MNP is an insensi­
tive biomarker for DINP exposure assessment 
because it further metabolizes to form oxida­
tive metabolites before being excreted in urine 
(Koch and Angerer 2007; Koch et al. 2007). 
In addition, MNP can be formed from DINP 
in the environment, but for DINP, as for 
other phthalates, no environmental sources 
of oxidative metabolites, including mono­
carboxy  iso  octyl phthalate (MCOP), are 
known (Staples et al. 1997). Based on urinary 
concentrations of the oxidative metabolites 
of DINP in 102 German subjects between 
6 and 80 years of age, the estimated median 
intake of DINP was 0.6 µg/kg/day (Wittassek 
and Angerer 2008); a previous estimate of 
< 1 µg/kg/day was based on the urinary con­
centrations of the less­sensitive biomarker 
of exposure to DINP, MNP (McKee et al. 
Address correspondence to A. Calafat, Centers for 
Disease Control and Prevention, National Center 
for Environmental Health, Division of Laboratory 
Sciences, 4770 Buford Hwy, NE, Mailstop F53, 
Atlanta, GA 30341 USA. Telephone: (770) 488­
7891. E­mail: Acalafat@cdc.gov
Supplemental Material is available online (doi: 
10.1289/ehp.1002316 via http://dx.doi.org/).
We thank J. Reidy for technical assistance.
The findings and conclusions in this report are those 
of the authors and do not necessarily represent the views 
of the Centers for Disease Control and Prevention.
The authors declare they have no actual or potential 
competing   financial interests.
Received 19 April 2010; accepted 22 September 
2010.
Selecting Adequate Exposure Biomarkers of Diisononyl and Diisodecyl 
Phthalates: Data from the 2005–2006 National Health and Nutrition 
Examination Survey
Antonia M. Calafat, Lee-Yang Wong, Manori J. Silva, Ella Samandar, James L. Preau Jr., Lily T. Jia, 
and Larry L. Needham
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Ba c k g r o u n d: High-molecular-weight phthalates, such as diisononyl phthalate (DINP) and 
  diisodecyl phthalate (DIDP), are used primarily as polyvinyl chloride plasticizers.
oBjectives: We assessed exposure to DINP and DIDP in a representative sample of persons 
≥ 6 years of age in the U.S. general population from the 2005–2006 National Health and Nutrition 
Examination Survey (NHANES).
Me t h o d s : We analyzed 2,548 urine samples by using online solid-phase extraction coupled to iso-
tope dilution high-performance liquid chromatography–tandem mass spectrometry.
re s u l t s: We detected monocarboxyisooctyl phthalate (MCOP), a metabolite of DINP, and mono-
carboxyisononyl phthalate (MCNP), a metabolite of DIDP, in 95.2% and 89.9% of the samples, 
respectively. We detected monoisononyl phthalate (MNP), a minor metabolite of DINP, much less 
frequently (12.9%) and at concentration ranges (> 0.8 μg/L–148.1 μg/L) much lower than MCOP 
(> 0.7 μg/L– 4,961 μg/L). Adjusted geometric mean concentrations of MCOP and MCNP were 
significantly higher (p < 0.01) among children than among adolescents and adults.
co n c l u s i o n s: The general U.S. population, including children, was exposed to DINP and DIDP. 
In previous NHANES cycles, the occurrence of human exposure to DINP by using MNP as the sole 
urinary biomarker has been underestimated, thus illustrating the importance of selecting the most 
adequate biomarkers for exposure assessment.
key w o r d s : biomonitoring, DIDP, DINP, exposure, human, NHANES, urine. Environ Health 
Perspect 119:50–55 (2011).  doi:10.1289/ehp.1002316 [Online 22 September 2010]Human exposure to diisononyl and diisodecyl phthalates
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 1 | January 2011  51
2004). Toxicokinetics data in animals and in 
humans suggest that the oxidative metabo­
lites are much more sensitive biomarkers of 
exposure to DINP than is MNP (Koch et al. 
2007; Silva et al. 2006b). Similarly, although 
only limited DIDP human exposure assess­
ment data exist to date (Silva et al. 2007a), 
based on animal data (Kato et al. 2007), oxi­
dative metabolites are also likely to be sensi­
tive biomarkers of exposure to DIDP.
Assessing human exposure to phthalates 
is of interest because of their potential adverse 
health effects, particularly among the young. 
Data for several phthalates are available, but 
exposure information for high­  molecular­
weight phthalates, including DINP and 
DIDP, is inadequate (i.e., based on the urinary 
concentrations of the hydrolytic monoesters) 
or rather limited (i.e., restricted to adults 
only). The aims of this study are 3­fold. First, 
we present for the first time nationally repre­
sentative data on the concentrations of oxida­
tive metabolites of DINP and DIDP in urine 
among those people in the U.S. general popu­
lation ≥ 6 years of age, stratified by age group, 
sex, and race/ethnicity. Second, we evaluate 
the exposure to DINP and DIDP, based on 
the urinary concentrations of their metabolites 
MCOP and monocarboxyisononyl phthalate 
(MCNP), respectively, according to select 
sociodemographic factors. Finally, we also dis­
cuss the validity of MNP as a biomarker of 
exposure to DINP and compare its sensitivity 
with that of MCOP.
Materials and Methods
Since 1999, the CDC has conducted the 
National Health and Nutrition Examination 
Survey (NHANES) annually. NHANES 
provides data, released in 2­year intervals, to 
evaluate the health and nutritional status of 
the civilian, noninstitutionalized U.S. popula­
tion of all ages. NHANES includes household 
interviews, standardized physical examina­
tions, and collection of medical histories and 
biological specimens. Some of these speci­
mens are used to assess exposure to environ­
mental chemicals.
For this study, we analyzed 2,548 spot 
urine specimens collected during one of three 
daily examination sessions from a one­third 
subset of 2005–2006 NHANES participants 
≥ 6 years of age. The representative design of 
the survey was maintained, because the subset 
was a random sample of the total NHANES 
population. The National Center for Health 
Statistics (NCHS) Institutional Review Board 
reviewed and approved the study protocol. All 
participants gave informed, written consent; 
parents or guardians provided consent for 
participants < 18 years of age.
The urine samples were shipped on dry 
ice to the National Center for Environmental 
Health at the CDC and stored at –20ºC or 
below until analyzed. The analytical method 
for measuring 15 phthalate monoesters, 
including MNP and oxidized metabolites of 
DINPs (MCOP) and DIDPs (MCNP), in 
100 µL urine has been described in detail 
elsewhere (Silva et al. 2007b). The analyti­
cal approach involved enzymatic hydro­
lysis of the conjugated species of phthalate 
metabolites, followed by online solid­phase 
extraction, separation with high­performance 
liquid chromatography, and detection by 
isotope­dilution negative ion electrospray 
ionization tandem mass spectrometry. We 
used the calibration curves constructed with 
mono(2,6­dimethyl­6­carboxyhexyl) phtha­
late (for MCOP), mono(2,7­dimethyl­7­
carboxyheptyl) phthalate (for MCNP), and 
mono(3,5,5­trimethyl­1­hexyl) phthalate (for 
MNP) and their isotopically labeled analogs 
as the internal standards for quantification, 
as described previously (Silva et al. 2007b). 
Calibration standards, quality control, and 
reagent blank samples were included in each 
analytical batch along with the study samples 
(Silva et al. 2007b).
Under our experimental conditions, 
MCOP and MCNP, the metabolites of DINP 
and DIDP, respectively, were not chromato­
graphically resolved, and both MCOP and 
MCNP eluted separately as broad peaks. For 
quantification, we integrated the whole area 
under the cluster of peaks encompassing the 
various isomers of MCOP and MCNP. The 
hydroxy­ and oxo­oxidative metabolites of 
DINP (Koch and Angerer 2007; Koch et al. 
2007) could not be separated adequately; as 
a result, we could not estimate their concen­
trations. The limits of detection (LODs)—
calculated as 3S0, where S0 is the standard 
deviation as the concentration approaches 
zero (Taylor 1987)—were 0.8 µg/L (MNP), 
0.7 µg/L (MCOP), and 0.6 µg/L (MCNP). 
We prepared low­concentration (4–9 µg/L) 
and high­concentration (27–58 µg/L) quality 
control materials with pooled human urine 
that was analyzed with standards, reagent 
blanks, and urine samples. The precision of 
measurements, expressed as the relative stan­
dard deviation of multiple measures, depend­
ing on the phthalate metabolite, was 8–10% 
for low­concentration and 6–10% for high­
concentration quality control samples.
We used SAS (version 9.2; SAS Institute 
Inc., Cary, NC) and SUDAAN (version 10; 
Research Triangle Institute; Research Triangle 
Park, NC) to perform statistical analyses. 
SUDAAN calculates variance estimates that 
account for the complex, clustered design of 
NHANES. As recommended by NCHS, we 
used sample population weights to produce 
estimates that are representative of the U.S. 
population. We used the log10­transformed 
urinary metabolite concentrations for the sta­
tistical analyses and assigned a value equal 
to the LOD divided by the square root of 2 
(Hornung and Reed 1990) to the concentra­
tions below the LOD.
We stratified age, reported in years at 
the last birthday, in four groups (6–11 years, 
12–19 years, 20–59 years, and ≥ 60 years). 
On the basis of self­reported data, we cate­
gorized race/ethnicity as non­Hispanic black, 
non­Hispanic white, and Mexican American. 
Participants not defined by these racial/ethnic 
categories (n = 195) were included only in the 
total popu  lation estimate. For each age, sex, 
and race/ethnic group, we calculated geometric 
means (GMs) (if the overall weighted frequency 
of detection was > 60%) and distribution per­
centiles for both volume­based (micrograms 
per liter) and creatinine­corrected concentra­
tions (micrograms per gram creatinine). We 
also determined weighted Pearson correlations 
among the creatinine­corrected concentrations 
(log10 transformed) of MCOP, MCNP, and 
MNP in the 334 samples with detectable con­
centrations of all three compounds. Statistical 
significance was set at p < 0.05.
We used multiple regression to examine 
whether several variables [i.e., age group, sex, 
race/ethnicity, creatinine concentration, house­
hold income, and examination session (i.e., 
morning, afternoon, evening)] were associated 
with the log10­transformed urine concentra­
tions of MCOP and MCNP. On the basis 
of questionnaire responses, annual household 
income was available in increments of $5,000 
(ranging from < $5,000 to > $75,000). We 
categorized income as < $20,000, $20,000–
$45,000, and > $45,000 to obtain a compara­
ble number of participants per group. For the 
multiple regression models, we used the vari­
ables described previously and all their possible 
two­way interactions to calculate the adjusted 
GM concentrations (in micrograms per liter) 
of MCOP and MCNP. These variables were 
log10 transformed, because the distributions of 
concentrations of these phthalate metabolites 
and creatinine were skewed.
To arrive at the final model for each analyte, 
we used backward elimination with SUDAAN 
to remove the nonsignificant interactions one 
at a time. Covariates with non  significant main 
effects were then removed one at a time, and 
the model was rerun to determine whether 
the beta coefficients for covariates with signifi­
cant main effects or interactions changed by 
> 10%. If any did, we retained the relevant 
non  significant covariate in the model. Once the 
backward procedure was completed, covariates 
and interactions between covariates were added 
back into the model one at a time to determine 
whether any were significant, in which case they 
were retained in the final model.
We also constructed a 2 × 2 table to exam­
ine the suitability of the urinary concentra­
tions of MNP and MCOP as DINP exposure 
biomarkers.Calafat et al.
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In most of the samples analyzed, we detected 
MCNP (89.9%). Similarly, we detected 
MCOP in most samples (95.2%), but we 
detected MNP much less frequently (12.9%). 
More important, in 82.4% of participants 
with detectable concentrations of MCOP, 
which is a sensitive biomarker of exposure to 
DINP, MNP, the hydrolytic metabolite of 
DINP, was undetectable (Table 1). The GM 
and selected percentile concentrations strati­
fied by age, sex, and race/ethnicity are given 
in Tables 2 and 3 for MCOP and MCNP, 
respectively, two metabolites that have not 
been evaluated previously in NHANES, 
and in the Supplemental Material for MNP 
[see Supplemental Material, Tables 1 and 2 
(doi:10.1289/ehp.1002316)].
Among the 334 persons for whom MNP, 
MCOP, and MCNP were detectable in 
the urine, we found statistically significant 
(p < 0.0001) good to moderate correlations 
between the creatinine­corrected concentra­
tions of MCOP and both MNP [Pearson 
correlation coefficient (R) = 0.63] (Figure 1) 
and MCNP (R = 0.46). We also observed a 
significant (p < 0.0001) but rather weak cor­
relation (R = 0.25) between the concentrations 
of MCNP and MNP (Figure 1). Of interest, 
the person with the highest concentration of 
MCOP also had the highest concentration 
of MNP.
The final MCOP and MCNP models 
included household income, age group, and 
log10 creatinine without significant inter­
actions between these covariates (Table 4). 
The log­corrected creatinine concentration 
increased as the log of the phthalate metab­
olite concentrations increased [for MCNP, 
β = 0.82 (95% confidence interval (CI), 
0.71–0.94]; for MCOP, β = 0.88 (95% CI, 
0.79–0.97)]. See Supplemental Material, 
Table 3 (doi:10.1289/ehp.1002316). Of 
interest, the R2 for the model adjusted for 
age and income was larger (11% for MCOP; 
13% for MCNP) than the R2 for the model 
unadjusted for these two variables (see 
Supplemental Material, Table 3). For both 
phthalate metabolites, adjusted GM concen­
trations for children were significantly higher 
(p < 0.01) than for all other age groups; 
differences between adolescents and adults 
and between younger and older adults did 
not reach statistical significance (Table 4). 
Adjusted GM concentrations for both MCNP 
and MCOP for persons in the high household 
income category were significantly higher than 
for those in the low category (for MCNP, p = 
0.004; for MCOP, p = 0.01). Persons in the 
medium income level had significantly higher 
adjusted GM concentrations of MCNP than 
those in the low­income level (p = 0.03); 
other differences between household income 
groups did not reach statistical significance 
(Table 4). If instead of using log10 creatinine 
as a variable in the model, we modeled the 
log10 MCOP and MCNP creatinine­corrected 
concentrations (in micrograms per gram crea­
tinine), the results were very similar to those 
presented in Table 4 (shown for MCNP in 
Supplemental Material, Table 4).
Table 1. 2 × 2 table for MCOP and MNP [unweighted no. of participants (weighted percent)].
MNP urinary concentrations
MCOP urinary concentrations
Detectable Nondetectable Total
Detectable 347 (12.9) 2 (0.02) 349 (12.9)
Nondetectable 2,100 (82.4) 99 (4.7) 2,199 (87.1)
Total 2,447 (95) 101 (5)
Table 2. GM (95% CI) and selected percentiles of MCOP concentrations in urine for the U.S. population ≥ 6 years of age: data from NHANES 2005–2006.a
  Percentile (95% CI)
GM (95% CI) 10th 25th 50th 75th 90th 95th n
Overall population
µg/L 5.39 (4.68–6.22) 1.20 (1.00–1.40) 2.40 (2.10–2.80) 5.10 (4.40–6.00) 10.9 (9.10–13.1) 25.5 (19.1–35.4) 54.4 (32.5–85.2) 2,548
µg/g creatinine 5.26 (4.54–6.10) 1.53 (1.30–1.72) 2.60 (2.28–2.92) 4.53 (3.95–5.11) 9.25 (7.64–11.2) 24.0 (17.1–30.8) 40.2 (30.3–55.2) 2,548
Age group
6–11 years
µg/L 8.52 (7.19–10.1) 2.50 (1.90–3.40) 4.80 (4.00–5.80) 8.90 (7.60–9.90) 15.0 (11.3–19.3) 26.4 (19.9–37.3) 40.3 (26.4–61.6) 356
µg/g creatinine 9.38 (8.08–10.9) 3.29 (2.99–4.26) 5.53 (4.77–6.39) 8.49 (7.66–10.1) 14.8 (12.2–18.7) 30.3 (20.0–38.8) 40.1 (28.2–57.3) 356
12–19 years
µg/L 6.61 (5.42–8.06) 1.60 (1.20–2.00) 3.40 (2.80–3.90) 6.30 (5.20–7.30) 11.9 (9.60–16.0) 28.4 (18.2–58.7) 63.2 (28.4–106) 702
µg/g creatinine 4.93 (4.10–5.93) 1.73 (1.34–1.98) 2.62 (2.26–3.02) 4.32 (3.61–4.89) 7.44 (5.93–11.0) 19.4 (12.4–31.8) 34.7 (24.1–58.3) 702
20–59 years
µg/L 5.19 (4.40–6.12) 1.10 (0.800–1.50) 2.20 (1.80–2.60) 4.70 (4.00–5.70) 10.7 (8.50–13.1) 26.0 (17.9–44.6) 64.8 (32.6–99.9) 1,040
µg/g creatinine 4.98 (4.22–5.87) 1.43 (1.21–1.69) 2.42 (2.11–2.78) 4.10 (3.66–4.63) 8.59 (7.05–10.9) 24.8 (15.3–35.4) 43.7 (32.2–69.8) 1,040
≥ 60 years
µg/L 4.25 (3.60–5.02) 1.00 (0.700–1.30) 2.10 (1.60–2.50) 3.70 (3.00–4.80) 8.20 (6.90–10.7) 20.1 (13.6–28.1) 37.0 (24.8–63.2) 450
µg/g creatinine 4.95 (4.11–5.95) 1.48 (1.14–1.81) 2.48 (1.82–3.13) 4.46 (3.64–5.61) 8.48 (7.29–10.3) 18.5 (14.7–25.2) 30.9 (24.3–50.5) 450
Sex
Male
µg/L 6.24 (5.25–7.42) 1.50 (1.30–1.60) 2.80 (2.40–3.20) 5.70 (4.70–6.90) 12.1 (10.2–15.1) 30.8 (19.0–58.8) 66.4 (33.8–122) 1,270
µg/g creatinine 5.01 (4.21–5.97) 1.40 (1.21–1.63) 2.32 (2.04–2.68) 4.29 (3.75–5.03) 8.44 (7.17–10.9) 21.6 (15.1–35.4) 44.6 (25.7–85.9) 1,270
Female
µg/L 4.69 (4.14–5.30) 1.00 (0.700–1.30) 2.10 (1.80–2.40) 4.50 (4.00–5.20) 9.30 (8.20–11.1) 21.5 (17.5–27.0) 41.7 (28.1–61.7) 1,278
µg/g creatinine 5.51 (4.75–6.39) 1.69 (1.39–2.08) 2.82 (2.56–3.17) 4.73 (4.23–5.33) 9.55 (8.26–12.2) 24.7 (17.3–30.3) 39.3 (30.3–45.0) 1,278
Race/ethnicity
Non-Hispanic white
µg/L 5.25 (4.40–6.27) 1.10 (0.900–1.40) 2.40 (2.00–2.70) 5.00 (4.10–6.20) 11.1 (8.60–13.6) 25.5 (17.7–43.5) 56.1 (28.1–88.5) 1,038
µg/g creatinine 5.53 (4.61–6.63) 1.60 (1.32–1.96) 2.78 (2.44–3.06) 4.81 (4.13–5.56) 10.0 (7.63–13.3) 25.2 (16.3–34.5) 39.3 (26.8–59.7) 1,038
Mexican American
µg/L 5.77 (4.84–6.87) 1.40 (1.20–1.60) 2.40 (2.10–2.90) 5.20 (4.50–5.70) 9.90 (8.50–12.0) 23.6 (14.9–49.7) 54.4 (23.0–185) 637
µg/g creatinine 5.19 (4.38–6.14) 1.49 (1.33–1.84) 2.52 (2.28–2.73) 4.50 (3.64–5.29) 8.04 (7.13–10.1) 19.5 (12.3–37.7) 43.6 (20.9–93.4) 637
Non-Hispanic black
µg/L 6.08 (5.60–6.61) 1.60 (1.40–1.80) 2.90 (2.60–3.30) 6.00 (5.10–6.70) 11.4 (10.4–13.0) 24.5 (20.3–28.1) 50.0 (32.0–70.3) 678
µg/g creatinine 4.28 (3.86–4.74) 1.40 (1.16–1.64) 2.14 (1.90–2.26) 3.67 (3.26–4.09) 7.60 (6.80–8.81) 17.1 (13.2–21.5) 31.8 (22.5–43.7) 678
aParticipants not defined by the three racial/ethnic groups shown were included only in the total population estimate. LOD = 0.7 µg/L. Human exposure to diisononyl and diisodecyl phthalates
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We also conducted weighted univariate 
and multiple logistic regressions to exam­
ine the association of the concentrations of 
MCOP and MCNP above the 95th percentile 
(an arbitrary value selected as an example of 
higher­than­average concentrations) with sex, 
age group, race/ethnicity, household income, 
and examination session. We found no cova­
riates significantly associated with the likeli­
hood of MCNP or MCOP exceeding the 
95th percentile (data not shown).
Discussion
We detected MCOP at concentrations rang­
ing from > 0.7 µg/L to 4,961 µg/L in 95.2% 
of persons examined. By contrast, MNP, the 
hydrolytic DINP metabolite, was detected in 
only 12.9% of people and at lower concen­
tration ranges (> 0.8–148.1 µg/L). The only 
DIDP metabolite evaluated, MCNP, was 
detected in 89.9% of persons at concentra­
tions of > 0.6–672.6 µg/L. These data suggest 
that at least 90% of the general U.S. popula­
tion is exposed to DINP and DIDP. These 
data are in agreement with previous evalua­
tions of the urinary concentrations of MCOP 
(Koch et al. 2007; Silva et al. 2006b) and 
MCNP (Silva et al. 2007a) among select pop­
ulations of adults in Germany and the United 
States that suggest that people are exposed 
to DINP and DIDP. The NHANES 2005–
2006 data presented here confirm widespread 
human exposure to DINP and DIDP and 
could be used to derive internal dose exposure 
estimates. Future NHANES data will also be 
useful to determine the existence of exposure 
trends. Of note, temporal increases in urinary 
concentrations of DINP metabolites among 
some segments of the German population 
may reflect changes in production and use 
patterns of DINP between 1988 and 2003 in 
Germany (Wittassek et al. 2007).
Consistent with expectations, urinary con­
centrations of MCOP and MNP, which are 
metabolites of the same parent compound, 
correlated well with each other. We also found 
a fair correlation between the urinary concen­
trations of MCNP and MCOP. Commercial 
DINP and DIDP formulations are complex 
mixtures of C8–C10 or C9–C11 phthalates, 
respectively, enriched in C9 (DINP) or C10 
(DIDP) isomeric phthalates (Kavlock et al. 
2002a, 2002b). The composition of the mix­
tures may vary depending on the manufactur­
ing process, but DIDP is likely present in the 
DINP technical mixtures and vice versa (Kato 
et al. 2007; Silva et al. 2006a).
Of interest, the person with the highest 
urinary concentration of MCOP in this study 
also had the highest urinary concentration of 
the hydrolytic metabolite of DINP, MNP. 
Table 3. GM (95% CI) and selected percentiles of MCNP concentrations in urine for the U.S. population ≥ 6 years of age: data from NHANES 2005–2006.a
Percentile (95% CI)
GM (95% CI) 10th 25th 50th 75th 90th 95th n
Overall population
µg/L 2.73 (2.50–2.98) < LOD 1.40 (1.20–1.50) 2.70 (2.40–3.00) 5.30 (4.80–5.90) 10.2 (8.80–11.9) 17.5 (14.0–21.4) 2,548
µg/g creatinine 2.66 (2.43–2.91) < LOD 1.47 (1.32–1.61) 2.48 (2.29–2.71) 4.48 (4.05–4.85) 8.67 (7.17–9.71) 13.2 (10.8–17.5) 2,548
Age group
6–11 years
µg/L 4.54 (3.94–5.24) 1.50 (0.90–2.00) 2.50 (2.20–3.10) 4.70 (4.00–5.60) 8.10 (6.80–9.60) 14.6 (10.8–19.1) 22.8 (16.7–35.3) 356
µg/g creatinine 5.00 (4.45–5.63) 1.67 (1.22–2.26) 3.01 (2.57–3.33) 5.06 (4.18–5.76) 7.48 (6.71–8.84) 16.1 (12.5–18.9) 23.5 (16.1–31.7) 356
12–19 years
µg/L 3.18 (2.74–3.68) 0.700 (< LOD–1.10) 1.80 (1.50–2.10) 3.30 (2.90–3.80) 6.00 (4.70–7.20) 10.3 (7.60–13.7) 16.5 (11.5–21.5) 702
µg/g creatinine 2.37 (2.04–2.75) 0.894 (< LOD–1.09) 1.51 (1.23–1.72) 2.18 (1.91–2.52) 3.64 (2.94–4.55) 6.26 (5.15–8.70) 10.7 (7.57–14.1) 702
20–59 years
µg/L 2.52 (2.22–2.85) < LOD 1.20 (1.10–1.40) 2.50 (2.20–2.80) 4.90 (4.20–5.70) 9.40 (7.60–12.6) 17.0 (12.6–24.2) 1,040
µg/g creatinine 2.42 (2.17–2.69) < LOD 1.34 (1.20–1.50) 2.21 (2.05–2.48) 3.95 (3.59–4.53) 7.46 (6.00–9.41) 11.2 (9.26–19.0) 1,040
≥ 60 years
µg/L 2.51 (2.15–2.92) 0.700 (< LOD–0.80) 1.10 (0.90–1.40) 2.40 (1.90–2.70) 4.70 (3.90–5.80) 10.1 (7.40–12.5) 14.7 (12.1–26.3) 450
µg/g creatinine 2.92 (2.46–3.46) 0.913 (< LOD–1.11) 1.58 (1.35–1.88) 2.72 (2.41–3.03) 4.60 (3.72–5.22) 9.40 (6.43–12.5) 14.6 (11.2–19.2) 450
Sex
Male
µg/L 3.16 (2.82–3.54) 0.800 (< LOD–1.00) 1.70 (1.40–1.90) 3.00 (2.70–3.50) 5.90 (5.10–6.90) 11.0 (8.80–14.0) 19.5 (14.0–28.0) 1,270
µg/g creatinine 2.53 (2.28–2.82) 0.894 (< LOD–1.02) 1.40 (1.27–1.54) 2.36 (2.14–2.56) 4.38 (3.74–5.04) 7.42 (6.47–8.88) 13.0 (9.40–19.5) 1,270
Female
µg/L 2.37 (2.13–2.65) < LOD 1.10 (1.00–1.30) 2.30 (2.00–2.70) 4.80 (4.30–5.30) 9.30 (7.60–11.5) 14.7 (13.1–18.2) 1,278
µg/g creatinine 2.79 (2.47–3.15) < LOD 1.52 (1.30–1.77) 2.65 (2.34–2.96) 4.51 (4.03–5.16) 9.41 (6.82–11.6) 13.5 (10.7–19.7) 1,278
Race/ethnicity
Non-Hispanic white
µg/L 2.67 (2.39–2.98) < LOD 1.30 (1.10–1.50) 2.60 (2.30–2.90) 5.30 (4.70–6.10) 10.1 (8.20–12.6) 17.6 (12.6–24.3) 1,038
µg/g creatinine 2.81 (2.51–3.14) < LOD 1.55 (1.36–1.75) 2.57 (2.34–2.85) 4.62 (4.10–5.19) 9.26 (7.00–10.8) 13.5 (10.3–23.5) 1,038
Mexican American
µg/L 2.72 (2.40–3.08) 0.700 (< LOD–0.90) 1.50 (1.20–1.80) 2.70 (2.40–3.20) 4.90 (4.30–5.70) 9.00 (7.00–12.4) 14.4 (9.00–26.8) 637
µg/g creatinine 2.45 (2.13–2.81) 0.824 (< LOD–1.12) 1.38 (1.26–1.53) 2.32 (2.14–2.60) 4.04 (3.64–4.58) 6.97 (5.73–8.14) 11.0 (7.89–19.1) 637
Non-Hispanic black
µg/L 3.18 (2.75–3.67) 0.700 (< LOD–1.10) 1.60 (1.30–2.00) 3.20 (2.70–3.80) 5.90 (4.90–7.30) 13.0 (9.50–14.6) 19.2 (14.6–30.5) 678
µg/g creatinine 2.24 (1.96–2.55)   0.752 (< LOD–0.925) 1.26 (1.06–1.41) 1.97 (1.78–2.37) 3.60 (3.25–4.24) 7.82 (6.38–10.4) 12.0 (10.1–17.4) 678
aParticipants not defined by the three racial/ethnic groups shown were included only in the total population estimate. LOD = 0.6 µg/L.
Figure 1. Correlation analyses of the log-transformed creatinine-corrected urinary concentrations of MNP 
and MCOP (A) and of MNP and MCNP (B).
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These data are in agreement with a previous 
report on the metabolism and elimination of 
four DINP metabolites, including MCOP 
and MNP, in a male adult volunteer after 
administration of a single oral dose of deuteri­
um­labeled DINP of 1.27 mg/kg body weight 
(Koch and Angerer 2007). In that individual, 
most of the DINP recovered in the urine was 
in the form of oxidative metabolites, includ­
ing MCOP, and only a very small percentage 
was in the form of MNP.
We observed that adjusted GM concen­
trations of MCOP and MCNP were depen­
dent upon age and income. The differences in 
urinary concentrations of MCOP and MCNP 
among the various demographic groups exam­
ined may reflect differences in the consump­
tion of food or use of consumer products 
containing DINP and DIDP, respectively. 
For the first time, we report here the urinary 
concentrations of some DINP and DIDP 
metabolites among school­age children and 
adolescents in the United States. Although we 
do not have data for toddlers and preschool­
age children, our data confirm that exposure 
to these two phthalates occurs at young ages.
Variability in a person’s exposure to phtha­
lates can result from changes in use of per­
sonal care products, diet, or other activities. 
Although the urinary concentrations of phtha­
late metabo  lites can be used to assess a person’s 
exposure at a single point in time, the predic­
tive ability of one spot sample to categorize 
exposure over longer time periods will differ 
among phthalate metabolites; for MCOP and 
MCNP this temporal variability is unknown. 
However, several reports suggest that, although 
some metabolites display more temporal vari­
ability than others, the concentrations of sev­
eral phthalate metabolites in a single urine 
sample can provide a reliable ranking to classify 
exposure of an individual to phthalates for up 
to several months (Adibi et al. 2008; Fromme 
et al. 2007; Hauser et al. 2004; Hoppin et al. 
2002; Peck et al. 2010; Teitelbaum et al. 
2008). Furthermore, despite this individual 
temporal variability, on a population basis (e.g., 
NHANES), the wide range of concentrations 
observed likely represents an average exposure 
scenario (i.e., urinary concentrations in the 
upper percentiles resulting from the collection 
of urine soon after a phthalate­related activity 
may be offset by concentrations in the lower 
percentiles of other persons who provided the 
urine specimen shortly before conducting the 
same activity).
Generating high­quality biomonitoring 
data requires state­of­the­art analytical chemi­
stry methods as well as controlled sampling 
protocols and quality control/quality assur­
ance procedures (Angerer et al. 2007; Calafat 
and Needham 2009; Koch and Calafat 2009; 
Needham et al. 2005). In addition, the proper 
interpretation of biomonitoring data requires 
an understanding of the toxicokinetics of the 
target compounds (Calafat et al. 2006; Calafat 
and Needham 2008; Koch and Calafat 2009). 
For example, a previous DINP exposure assess­
ment by McKee at al. (2004) illustrates the 
critical importance of absorption, distribu­
tion, metabolism, and excretion information. 
Specifically, these authors concluded that expo­
sure to DINP in the United States was limited 
(McKee et al. 2004), based on an analysis of 
NHANES 1999–2000 biomonitoring urinary 
data (CDC 2009; Silva et al. 2004). However, 
their estimates were based solely on urinary 
concentrations of MNP, an insensitive bio­
marker of environmental exposure to DINP.
Although the frequency of detection and 
concentration ranges of MNP in NHANES 
2005–2006 and NHANES 1999–2000 are 
quite similar (Silva et al. 2004), NHANES 
2005–2006 data for MCOP suggest that 
> 90% of the U.S. general population is 
exposed to DINP, a much greater percentage 
than suspected based on previous NHANES 
estimates using MNP measurements only. 
Furthermore, these data also suggest that 
MNP is a rather insensitive biomarker of 
background exposures, because it is only a 
minor metabolic product of DINP in humans 
(Koch and Angerer 2007; Koch et al. 2007). 
In contrast, MCOP, a major metabolite of 
DINP, appears to be a sensitive indicator 
of DINP exposure. In fact, 82.4% of those 
classi  fied as exposed to DINP would have 
been misclassified as unexposed based on uri­
nary concentrations of MNP only. Therefore, 
we recommend that future biomonitoring 
studies, particularly those focused on envi­
ronmental exposures, rely on MCOP or other 
oxidative metabolites and not solely on MNP.
Conclusions
We measured the urinary concentrations of 
one oxidative metabolite (MCOP) and the 
hydrolytic metabolite (MNP) of DINP, as 
well as MCNP, an oxidative metabolite of 
DIDP, in the general U.S. population. MCOP 
and MCNP were detectable in most persons 
examined, whereas MNP was detected in only 
about 12%. These NHANES data suggest that 
the U.S. general population is often exposed 
to DIDP and DINP and highlights the need 
for additional studies to identify potential 
sources of DINP and DIDP. Of interest, the 
significantly higher frequency of detection 
and urinary concentrations of MCOP than 
of MNP confirm the validity of MCOP as 
a biomarker for DINP exposure assessment 
and suggests widespread exposure to DINP. 
More important, these NHANES data suggest 
that the occurrence of exposure to DINP has 
been underestimated by using MNP as the 
sole DINP urinary biomarker.
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